Polyfunctional strength index identifies responders to combination immunotherapy in acute myeloid leukemia
ORLANDO — Polyfunctional strength index on pretherapy bone marrow CD4-positive T cells differed substantially between responders and nonresponders to azacitidine plus nivolumab for relapsed or refractory acute myeloid leukemia, according to results of a nonrandomized phase 2 study presented at ASH Annual Meeting and Exposition. This finding may indicate an immune diversity in AML and a need
